Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Journal:

Journal of Clinical Oncology

Published:

2025-12-08

DOI:

10.1200/jco-25-02477

Affiliations:

24

Authors:

28

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	7.000000	0.25
Maria Sklodowska-Curie National Research Institute of Oncology, Poland	1.000000	0.04
Perth Blood Institute (PBI), Australia	1.000000	0.04
Haihe Laboratory of Cell Ecosystem, China	1.000000	0.04
Center for Integrated Oncology Aachen Bonn Köln Düsseldorf (CIO), Germany	1.000000	0.04
Hospital Mãe de Deus, Brazil	1.000000	0.04
Onkozentrum Dresden/Freiberg/Meißen, Germany	1.000000	0.04
University of California, Irvine (UCI), United States of America (USA)	1.000000	0.04
Wroclaw Medical University, Poland	1.000000	0.04
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), China	1.000000	0.04
The Oncology Institute of Hope and Innovation, United States of America (USA)	1.000000	0.04
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.04
OSU Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), United States of America (USA)	1.000000	0.04
Medical University of Silesia (SUM), Poland	1.000000	0.04
Nicolaus Copernicus University in Toruń (NCU), Poland	1.000000	0.04
University Hospital Brno, Czech Republic	1.000000	0.04
Inmunocel, Chile	1.000000	0.04
Ankara University, Turkey	1.000000	0.04
Centre Henri Becquerel, France	1.000000	0.04
Centre Hospitalier du Mans, France	1.000000	0.04
Sir Charles Gairdner Hospital (SCGH), Australia	0.500000	0.02
Catholic Hematology Hospital, South Korea	0.500000	0.02
Seoul St. Mary's Hospital, South Korea	0.500000	0.02
The University of Western Australia (UWA), Australia	0.500000	0.02

Interested in Cardiovascular Medicine and Haematology?